Amplitude Healthcare Acquisition Corporation
AMHCU
NASDAQ Capital Market10.96
USD
+0.36
- -
CIK
0001788028
ISIN
US03212A2042
CUSIP
03212A204
Return %
Stock
S&P500
1Y
- -
18.21
3Y
- -
64.38
5Y
10.15
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Balaji Venkataraman
- Full Time Employees
- 1
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1177 Avenue of the Americas New York City NY United States of America 10036
- IPO Date
- Nov 20, 2019
- CIK
- 0001788028
- Website
- amplitudehealthcare.com
- Similar Companies
- Business
- Amplitude Healthcare Acquisition Corporation Amplitude Healthcare Acquisition Corporation (AMHCU) is a blank check company, or special purpose acquisition company (SPAC), formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company focuses on target opportunities within the healthcare sector, including pharmaceuticals, biotechnology, medical devices, and healthcare services, primarily in the United States and Europe; it currently conducts no significant operations and generates no revenue while maintaining proceeds from its initial public offering in trust pending a qualifying transaction. Incorporated in the state of Delaware in 2019 and headquartered in New York, New York, Amplitude Healthcare Acquisition Corporation maintains a lean structure with a small team experienced in healthcare investing and corporate finance, targeting companies with established product pipelines, scalable operations, and strong growth potential in North America. In 2021, the company entered into a definitive business combination agreement with Jasper Therapeutics, Inc., a clinical-stage biotechnology firm developing therapies for hematopoietic cell transplant-related conditions, supported by a $100 million PIPE financing from investors including Amgen, Roche Venture Fund, and others; shareholder approval followed, with the combined entity listing on Nasdaq under the ticker JSPR and an expected initial market capitalization of approximately $490 million. As of late 2025, the company trades on the OTC Markets under AMHCU with units reflecting recent prices around $14.65 to $16.28, and it continues to evaluate potential partners without further announced major transactions in the past 1-2 years.